Cellular Aging Patterns Linked to Neurodegenerative Diseases and Mortality Risk

A groundbreaking study published in Nature reveals that cell types age at distinct rates, with plasma protein signatures offering new insights into disease susceptibility and mortality risk. Researchers analyzed single-cell transcriptomic data from the Human Protein Atlas, linking 60 cell types to plasma proteins and identifying age-related patterns across 7,074 healthy individuals in the Global Neurodegeneration Proteomics Consortium (GNPC).

How Does Cellular Aging Relate to Neurodegenerative Diseases?

Cellular aging signatures were strongly associated with neurodegenerative conditions, including Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS), and Parkinson’s disease (PD). For instance, ALS patients exhibited accelerated aging in skeletal myocytes (r = 0.43, adjusted P = 1.36×10−15) and cardiomyocytes (r = 0.33, adjusted P = 4.08×10−9), aligning with emerging evidence of cardiac abnormalities in ALS patients. AD was linked to accelerated aging in oligodendrocyte precursor cells (r = 0.15, adjusted P = 1.86×10−44) and inhibitory neurons, highlighting the systemic nature of AD pathophysiology.

What Role Does APOE Genotype Play in Cellular Aging?

The APOE genotype, a major risk factor for AD, showed dose-dependent effects on cellular aging. APOE2 carriers had younger astrocyte profiles but older macrophages, while APOE4 carriers exhibited the opposite pattern. This antagonistic pleiotropy suggests evolutionary trade-offs, where APOE4’s immune benefits may increase AD risk in modern lifespans. APOE4 homozygotes with extreme astrocyte aging had a 38.3% cumulative AD incidence over 15 years, compared to 12.6% for those with normal aging.

How Do Cellular Aging Patterns Predict Mortality Risk?

Extreme aging in muscle lineage cells (HR = 4.38) and skeletal myocytes (HR = 4.18) strongly predicted all-cause mortality over 15 years in the UK Biobank (UKB). A polycellular aging risk score (PARS) incorporating 15 cell types stratified mortality risk effectively, with high-risk individuals showing 34% survival over 15 years compared to 90% for normal agers. The PARS model, validated across proteomics platforms, demonstrated platform-agnostic prognostic value.

What Are the Implications for Disease Prevention and Treatment?

These findings suggest that targeting cellular aging could mitigate disease risk. For example, youthful astrocytes reduced AD risk by over 60%, while extreme skeletal myocyte aging increased ALS risk 12.74-fold. The study also identified potential therapeutic targets, such as NEFL-C1QL2 projection neurons for FTD and myeloid lineage cells for type 2 diabetes. Researchers emphasize the need for interventions preserving cellular health, particularly in genetically predisposed populations.

What Are the Limitations and Future Directions?

While the study links cellular aging to disease outcomes, causal mechanisms remain unclear. Longitudinal data from the NSHD cohort showed that 55% of macrophage extreme agers retained their status over 10 years, suggesting stable aging profiles. Future research will explore how lifestyle factors, such as exercise and diet, influence cellular aging trajectories. The integration of multi-omics data may further refine aging biomarkers and therapeutic strategies.

As Dr. Natalie Singh, a board-certified internal medicine physician and MPH, notes, “These discoveries underscore the importance of personalized medicine. By understanding how individual cells age, we can develop targeted interventions to delay disease onset and improve healthspan.”